The Boston Scientific ACCESS Trial
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The Boston Scientific ACCESS trial seeks to study the safety and to evaluate the success of the Fusion™ Vascular Access Graft for patients in need of early vascular access for hemodialysis.
| Condition | Intervention | Phase |
|---|---|---|
|
Renal Disease Kidney Failure |
Device: vascular access graft implantation |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | ACCESS: Prospective, Multi-center Trial of the Fusion Vascular Access Graft for Patients Who Require Early Vascular Access for Hemodialysis |
- Secondary patency at 6 months as determined by ability of the graft to be used for vascular access for hemodialysis [ Time Frame: 6 Months ] [ Designated as safety issue: Yes ]
| Enrollment: | 149 |
| Study Start Date: | December 2005 |
| Study Completion Date: | December 2008 |
| Primary Completion Date: | May 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Arm 1 |
Device: vascular access graft implantation
vascular access graft implantation
|
Detailed Description:
The Boston Scientific ACCESS trial seeks to study the safety and to evaluate the success of the Fusion™ Vascular Access Graft for patients in need of early vascular access for hemodialysis. The primary objective is to demonstrate that secondary patency at 6 months for the Fusion™ Vascular Access Graft is not less than an objective performance criterion (OPC) minus a clinically relevant margin (δ). The OPC represents secondary patency at 6 months for the standard of care access grafts.
The secondary safety endpoint is the occurrence of CEC-adjudicated device or procedure related adverse events through 24 months post implant procedure, or through discharge for patients with unsuccessful device implantation. Secondary efficacy endpoints include:primary patency; primary assisted patency; ability to revise a failed graft; early access capability; time to hemostasis.
Subjects will undergo a thorough medical assessment and physical examination pre-procedure and will be assessed peri-procedure. Enrolled subjects with a device implanted will be evaluated at 1, 6, 12, 18 and 24 months post implant procedure.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Need for early dialysis access (≤72 hours after implantation):
- Initiation of maintenance dialysis is recommended per K/DOQI or institutional guidelines; or
- Patient is currently receiving dialysis via catheter
- No prior implantation of synthetic graft in the arm to be treated
- Life expectancy of at least 2 years, based on physician's assessment of medical condition
Exclusion Criteria:
- Patient younger than 18 years of age
- Any stenosis in the veins proximal to (downstream of) implant site, as determined previously or by current ultrasound
- Pregnancy
- Bleeding disorder, e.g., low platelet count (<50,000), hypercoagulable state, e.g., antithrombin III deficiency; antiphospholipid or anticardiolipin antibodies; Factor V Leiden; circulating Lupus anticoagulant; current, active heparin-induced thrombocytopenia; Protein C or S deficiency; or history of recurrent deep vein thrombosis not related to AV access.
- Active malignancy, e.g., condition either being treated or considered untreatable
- Active systemic infection, e.g., condition either being treated or considered untreatable
- Uncontrolled major symptomatic medical problem, e.g., undiagnosed severe pain, metabolic disturbance, fever, etc.
- Likelihood of poor compliance to required dialysis protocol, e.g., history of poor attendance to required clinic sessions or non-compliance to medication
- Mental incapacity; inability to understand treatment instructions
- Currently participating in another investigational drug or device study that clinically interferes with the endpoints of this study
Contacts and Locations| United States, California | |
| Long Beach VA Medical Center | |
| Long Beach, California, United States, 90822 | |
| United States, Georgia | |
| Saint Joseph's Hospital of Atlanta | |
| Atlanta, Georgia, United States, 30342 | |
| United States, Illinois | |
| Rush University Medical Center | |
| Chicago, Illinois, United States, 60612-3824 | |
| United States, Massachusetts | |
| Beth Israel Deaconess Medical Center | |
| Boston, Massachusetts, United States, 02215 | |
| United States, New Jersey | |
| VA New Jersey Healthcare System | |
| East Orange, New Jersey, United States, 07018 | |
| United States, New York | |
| New York - Presbyterian, Columbia University Medical Center | |
| New York, New York, United States, 10032 | |
| United States, Ohio | |
| Cleveland Clinic Foundation | |
| Cleveland, Ohio, United States, 44195 | |
| United States, Texas | |
| University of Texas Southwestern / VA Medical Center | |
| Dallas, Texas, United States, 75216 | |
| Principal Investigator: | Luis Sanchez, MD | Washington University School of Medicine, Barnes Jewish Hospital |
More Information
No publications provided
| Responsible Party: | Maquet Cardiovascular |
| ClinicalTrials.gov Identifier: | NCT00260728 History of Changes |
| Other Study ID Numbers: | S2100, G050151 |
| Study First Received: | November 30, 2005 |
| Last Updated: | June 26, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Maquet Cardiovascular:
|
vascular access hemodialysis |
Additional relevant MeSH terms:
|
Kidney Diseases Renal Insufficiency Urologic Diseases |
ClinicalTrials.gov processed this record on May 16, 2013